An additional dose of canagliflozin @ mg ( Treatment C ) , but not @ mg ( Treatment D ) , prior to the MMTT on Day @ provided greater postprandial PG reduction versus placebo ( difference in incremental glucose AUC@-@h , -@ % for B vs A ; -@ % for C vs A ; -@ % -LSB- P = @ -RSB- for C vs B ) , leading to modestly greater reductions in total glucose AUC@-@h with Treatment C versus Treatment B or D. Canagliflozin was generally well tolerated .